Fundraising FoxJDRF T1D Fund — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases.
BiotechHealthtechMedical Devices
Robert Geho(Co-Founder, Chief Executive Officer)inW. Blair Geho(Co-Founder, Chief Scientific Officer)in
Co-investorsMedicxi
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Co-investorsAlumni Ventures+ND CapitalGV (Google Ventures)Illumina VenturesInvusQuark Venture Inc.+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.